Vir Biotechnology has been granted a patent for multispecific antibodies that target distinct Zika virus epitopes, effectively neutralizing ZIKV infection. The patent also covers nucleic acids encoding these antibodies for prophylaxis and treatment of ZIKV. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of February 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Multispecific antibodies for zika virus infection treatment
A recently granted patent (Publication Number: US11926658B2) discloses an isolated multispecific antibody or antigen binding fragment specifically targeting at least two distinct Zika virus epitopes. The antibody comprises a unique combination of amino acid sequences in its heavy and light chains, as detailed in the patent claims. Furthermore, the antibody is designed to neutralize Zika virus infection, showcasing its potential therapeutic application in combating the virus.
Moreover, the patent highlights the versatility of the antibody, indicating that it can be bispecific, trispecific, tetraspecific, or pentaspecific, offering a wide range of targeting capabilities. Additionally, the antibody can exhibit different valencies, such as bivalent, trivalent, tetravalent, hexavalent, or octavalent, further enhancing its efficacy. The inclusion of an Fc moiety in the antibody structure and its compatibility with various antibody formats like Fabs-in-tandem-Ig and DVD-Ig underscore the innovation and adaptability of this antibody in potential pharmaceutical compositions and kits for Zika virus management.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
